RECRUITING

Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance

Description

Prostate cancer is the most commonly diagnosed cancer in men. However, there is a wide range in prognosis determined by a host of factors. This study will evaluate the feasibility of guiding therapeutic intervention electronically facilitated symptom and disease monitoring in patients being followed on Active Surveillance. Additionally, we will develop a tissue and data resource to support discovery and hypothesis generation to evaluate germline and/or somatic alterations in relation to cancer-specific and overall outcomes..

Conditions

Prostate Cancer
Talk to us

Related Conditions:

Prostate Cancer

Study Overview

On this page

Study Details

Study overview

Prostate cancer is the most commonly diagnosed cancer in men. However, there is a wide range in prognosis determined by a host of factors. This study will evaluate the feasibility of guiding therapeutic intervention electronically facilitated symptom and disease monitoring in patients being followed on Active Surveillance. Additionally, we will develop a tissue and data resource to support discovery and hypothesis generation to evaluate germline and/or somatic alterations in relation to cancer-specific and overall outcomes..

Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance

Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance

Condition
Prostate Cancer
Intervention / Treatment

-

Contacts and Locations

Houston

M D Anderson Cancer Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patients will have histologic diagnosis of adenocarcinoma of the prostate within 24 months of study entry.
  • 2. Patient must meet at least one of the following clinical indications for AS: National Comprehensive Cancer Network (NCCN) very low risk or low risk prostate cancer meeting consensus guidelines for AS; NCCN intermediate-risk prostate cancer requesting AS (per patient and clinician shared decision making); or have severe medical comorbidities (defined as CCI estimated 10-year survival \< 50% and agreed by treating clinician) with high- or very high-risk localized prostate cancer.
  • 3. Patients must agree to comply with the surveillance schedule.
  • 4. Patients must be over 18 years of age
  • 5. Written informed consent
  • 6. Patients must be fluent in the English language to participate in the patient report outcome and symptoms monitoring portion of the trial.
  • 1. Patients are ineligible if they choose not to share their medical data for research purposes.
  • 2. Prior radiation therapy for treatment of the primary tumor.
  • 3. Planned concomitant hormonal therapy, chemotherapy, or radiation therapy while on protocol

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

M.D. Anderson Cancer Center,

Christopher Logothetis, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

2029-07-30